MYOS - ミオス (MYOS RENS Technology Inc.) ミオス

 MYOSのチャート


 MYOSの企業情報

symbol MYOS
会社名 MYOS RENS Technology Inc (ミオス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 食品加工   一般消費財(Consumer Products)
概要 事業概要 MYOS RENS Technology Inc. (MYOS) formerly MYOS Corporation is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery development and commercialization of products that improve muscle health and function essential for the management of sarcopenia cachexia and degenerative muscle diseases and as an adjunct to the treatment of obesity. The Company is focused on the discovery development and commercialization of nutritional supplements functional foods therapeutic products and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions including sarcopenia cachexia and inherited and acquired muscle diseases. The Company through its subsidiary holds the intellectual property pertaining to Fortetropin which is a dietary supplement.   ミオスは、米国のバイオ医薬品会社。栄養補助サプリメントや健康食品などの研究、開発、製造、販売に従事。主に、筋肉の健康維持と増強に焦点を当てている。ダイエタリ―・サプリメントの抗ミオスタチン阻害剤「MYO-T12」の商標を有す。本社は、ニュ―ジャ―ジ―州シダ―・ノ―ルズ。   MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.
本社所在地 45 Horsehill Road Suite 106 Cedar Knolls NJ 07927 USA
代表者氏名 Robert J. Hariri ロバート・J・ハリリ
代表者役職名 Independent Chairman of the Board
電話番号 +1 973-509-0444
設立年月日 39173
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 10人
url www.myosrens.com
nasdaq_url https://www.nasdaq.com/symbol/myos
adr_tso
EBITDA EBITDA(百万ドル) -3.75100
終値(lastsale) 1.1716
時価総額(marketcap) 8756213.8668
時価総額 時価総額(百万ドル) 8.59553
売上高 売上高(百万ドル) 0.46200
企業価値(EV) 企業価値(EV)(百万ドル) 8.08753
当期純利益 当期純利益(百万ドル) -0.38600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MYOS RENS Technology Inc revenues decreased 31% to $145K. Net loss increased 1% to $2.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Sales and marketing increase of 29% to $629K (expense) Personnel and benefits increase of 15% to $765K (expense).

 MYOSのテクニカル分析


 MYOSのニュース

   85 Stocks Moving In Wednesday's Mid-Day Session  2020/08/05 12:02:00 Benzinga
Gainers Biofrontera AG (NASDAQ: BFRA) climbed 151.8% to $14.10. MYOS RENS Technology Inc. (NASDAQ: MYOS) shares climbed 73.4% to $2.15 after the company …
   MYOS RENS Technology's Net Revenues Increase 114% and Operating Expenses Decrease 26% for the Three Months Ended June 30, 2020  2020/08/05 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., Aug. 5, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announces its results for the three and six…
   MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.  2020/07/16 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., July 16, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates MYOS RENS Technology Inc.  2020/07/08 01:30:00 PR Newswire
NEW YORK, July 7, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) in connection with the proposed merger of the Company with…
   University of California, Berkeley Researchers Publish Clinical Results Reporting that Fortetropin® Increased the Rate of Muscle Protein Synthesis in Older Adults  2020/07/07 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle,…
   85 Stocks Moving In Wednesday's Mid-Day Session  2020/08/05 12:02:00 Benzinga
Gainers Biofrontera AG (NASDAQ: BFRA) climbed 151.8% to $14.10. MYOS RENS Technology Inc. (NASDAQ: MYOS) shares climbed 73.4% to $2.15 after the company …
   MYOS RENS Technology's Net Revenues Increase 114% and Operating Expenses Decrease 26% for the Three Months Ended June 30, 2020  2020/08/05 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., Aug. 5, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announces its results for the three and six…
   MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.  2020/07/16 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., July 16, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates MYOS RENS Technology Inc.  2020/07/08 01:30:00 PR Newswire
NEW YORK, July 7, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) in connection with the proposed merger of the Company with…
   University of California, Berkeley Researchers Publish Clinical Results Reporting that Fortetropin® Increased the Rate of Muscle Protein Synthesis in Older Adults  2020/07/07 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle,…
   85 Stocks Moving In Wednesday's Mid-Day Session  2020/08/05 12:02:00 Benzinga
Gainers Biofrontera AG (NASDAQ: BFRA) climbed 151.8% to $14.10. MYOS RENS Technology Inc. (NASDAQ: MYOS) shares climbed 73.4% to $2.15 after the company …
   MYOS RENS Technology's Net Revenues Increase 114% and Operating Expenses Decrease 26% for the Three Months Ended June 30, 2020  2020/08/05 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., Aug. 5, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announces its results for the three and six…
   MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.  2020/07/16 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., July 16, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates MYOS RENS Technology Inc.  2020/07/08 01:30:00 PR Newswire
NEW YORK, July 7, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) in connection with the proposed merger of the Company with…
   University of California, Berkeley Researchers Publish Clinical Results Reporting that Fortetropin® Increased the Rate of Muscle Protein Synthesis in Older Adults  2020/07/07 12:00:00 PR Newswire
CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle,…

 関連キーワード  (食品加工 米国株 ミオス MYOS MYOS RENS Technology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)